Independent analysis puts a KP semaglutide lot at 95.6%, against 94.1% on the certificate

Medutest has published a purity determination of 95.6% on a 10 mg vial of semaglutide supplied by KP, against a figure of 94.1% on the certificate that accompanied the vial. The sample was submitted by the Journal in October 2025 as part of a continuing programme of arm’s-length purchasing, and the vendor was told before the order was placed that any result would be published.

The Journal purchased 1600 vials from the same lot and had 17 of them analysed separately, in order to distinguish vial-to-vial variation from method variation. Vial-to-vial agreement was within 0.4 percentage points. Method-to-method disagreement was an order of magnitude larger.

Reported figures across the set were: highest 95.6%, lowest 94.1%, median close to the midpoint of the two. Every report in the set stated a detection wavelength, and 17 of them stated an integration threshold. The Journal has asked the laboratory to publish thresholds on all reports as a matter of routine.

Discrepancies of one to two percentage points between a supplier’s figure and an independent determination are common and usually explicable: a faster gradient resolves fewer impurities, a higher integration threshold discards more small peaks, and a wider solvent-front exclusion window removes early-eluting fragments from the calculation altogether. None of that is misconduct. All of it is invisible unless the method is disclosed.

"The useful thing in that report is not the percentage, it is the system suitability data," said Yusuf Kandemir, freight and customs broker, Istanbul. "It is the only part that tells you whether the percentage means anything."

KP’s dossier has been updated with this determination and with the date of the request for comment. The dossier’s "what we could not verify" box records the questions still outstanding.